Overview

Comparison of High-dose IL-2 and High-dose IL-2 With Radiation Therapy in Patients With Metastatic Melanoma.

Status:
Active, not recruiting

Trial end date:
2022-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is compare the response rates in patients with metastatic melanoma treated with high-dose IL-2 to patients treated with high-dose IL-2 along with radiation therapy.

Phase:

Phase 2

Details

Lead Sponsor:

Providence Health & Services

Collaborator:

Prometheus Laboratories

Treatments:

Interleukin-2